Showing 5331-5340 of 5621 results for "".
- University of Alberta Scientists Pinpoint a Cause of Pigmentary Glaucomahttps://modernod.com/news/university-of-alberta-scientists-pinpoint-a-cause-of-pigmentary-glaucoma/2476337/An international team of researchers has identified a gene responsible for the onset of pigmentary glaucoma, which may lead to new therapies for the condition. “People who traditionally we wouldn’t think of having glaucoma—young males in their 20s and 30s—are at particular risk
- Investigators Seek Optimized Ophthalmology Clinical Trial Outcomeshttps://modernod.com/news/investigators-seek-optimized-ophthalmology-clinical-trial-outcomes/2476338/Investigators from Brown University and Johns Hopkins University shared new considerations from 3 groups working to standardize Core Outcome Sets (COSs), to increase the utility of results from randomized clinical trials for 3 eye conditions: age-related macular degeneration (AMD), refractive err
- Ranibizumab and Aflibercept Prompt Comparable Visual Gain in AMDhttps://modernod.com/news/ranibizumab-and-aflibercept-prompt-comparable-visual-gain-in-amd/2476339/In patients with neovascular age-related macular degeneration (AMD), aflibercept and ranibizumab achieve similar average visual acuity increases, according Australian researchers, as reported by Reuters. In a January 24 online paper in JAMA Ophthalmology, Dr. Mark C. Gillies of Sy
- Lutronic Vision Initiates Preclinical Trial of R:GEN Laser for the Treatment of Dry AMDhttps://modernod.com/news/lutronic-vision-initiates-preclinical-trial-of-rgen-laser-for-the-treatment-of-dry-amd/2476343/Lutronic Vision announced that it has initiated a preclinical trial to determine the optimal setting for its R:GEN laser for the treatment of the dry form of age-related macular degeneration (AMD). This study has been initiated at the University of Southern California with Stan Louie, PharmD, Pr
- Controlled Trial Shows Promise of Donated Stem Cells in Restoring Visionhttps://modernod.com/news/controlled-trial-shows-promise-of-donated-stem-cells-in-restoring-vision/2476345/A study in STEM CELLS Translational Medicine provides a deeper and clearer understanding of how patients suffering vision loss in both eyes due to limbal stem cell deficiency (LSCD) might benefit from a stem cell transplant using donated cells. This is the first ra
- Multicolor Holography Technology Could Enable Extremely Compact 3D Displayshttps://modernod.com/news/multicolor-holography-technology-could-enable-extremely-compact-3d-displays/2479595/Researchers have developed a new approach to multicolor holography that could be used to make 3D color displays for augmented reality glasses, smartphones, or heads-up displays without any bulky optical components. In Optica, researchers from Duke University, describe how they encod
- Nicox Announces FDA Acceptance of Investigational NDA for NCX 4251 Phase 2 Trial in Blepharitishttps://modernod.com/news/nicox-announces-fda-acceptance-of-investigational-nda-for-ncx-4251-phase-2-trial-in-blepharitis/2479597/Nicox SA announced that the FDA has completed its review of the company’s investigational new drug (IND) application for NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals, being developed as the fi
- Tangible Science Introduces Lens Care System for Custom Contact Lenses Coated with Tangible Hydra-PEGhttps://modernod.com/news/tangible-science-introduces-lens-care-system-for-custom-contact-lenses-coated-with-tangible-hydra-peg/2479600/Tangible Science will be unveiling at the Global Specialty Lens Symposium this week its complete system of products designed to ensure that custom contact lenses coated with Tangible Hydra-PEG offer benefit for the prescribed life of the lenses. Tangible Hydra-PEG is a unique polymer coati
- Nicox Establishes High-Profile Glaucoma Clinical Advisory Boardhttps://modernod.com/news/nicox-establishes-high-profile-glaucoma-clinical-advisory-board/2479601/Nicox SA announced the formation of Nicox Glaucoma Clinical Advisory Board, composed of key clinical investigators and opinion leaders in the field, to support and guide the development of its innovative NO-donating compounds as potential IOP-lowering drugs.
- Bruder Announces Eyeleve Contact Lens Compresshttps://modernod.com/news/bruder-announces-eyeleve-contact-lens-compress/2479603/Bruder Healthcare announces the immediate availability of Eyeleve, a compress clinically proven to increase comfortable contact lens wear time by up to 3 hours daily. The Eyeleve Contact Lens Compress delivers consistent, therapeutic moist heat that alleviates symptoms of meibomian gland d